Fondaparinux requires further study before firm recommendation [3]

Archives of Internal Medicine

Volumn 163, Issue 4, 2003, Pages 498-

  Hughes, Steven J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIP FRACTURE; HUMAN; LETTER; LUNG EMBOLISM; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; THROMBOEMBOLISM;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FRACTURE FIXATION, INTERNAL; GREAT BRITAIN; HIP FRACTURES; HUMANS; POLYSACCHARIDES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0037463611     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.4.498a     Document Type: Letter

References (4)

1. Heit JA. The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med. 2002;162:1806-1808.
2. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162:1833-1840.
3. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet. 2002;359:1710-1711.
4. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.